Concordia inks deal with Japan's Ono; Elan shareholder to propose new board members;

 @FierceBiotech: Nobel Prize-winner finds new path for Alzheimer's drug. Story | Follow @FierceBiotech

 @JohnCFierce: Forbion Capital raised €190 million for a new fund. Good news for European biotechs. | Follow @JohnCFierce

> Concordia Pharmaceuticals has signed a licensing agreement with Japan's Ono Pharmaceutical for salirasib, a treatment for pancreatic, non-small cell lung and colorectal cancers. The agreement grants Ono the exclusive rights to develop and commercialize salirasib in Japan. Concordia release

> Next week, dissident shareholder Ib Sonderby plans to hold a conference call to introduce four proposed board members he would like to install at Elan. Report

> Gilead Sciences has sumited a marketing authorization application to the EMA for approval for the fixed-dose combination of Truvada for HIV-1 infection in adults. Gilead release

> Over the previous decade, the proportion of Americans (of all ages) reporting they took a prescription drug in the past month rose to 48 percent from 44 percent. Report

And Finally... Can cranberry juice prevent staph infections? Story

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.